http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-089408-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ab1148d954634afed3d6824bb0832823 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-07048 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-173 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D473-18 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-708 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-207 |
| filingDate | 2012-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9d235bb70ba67476d8f647b98d1283f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e592133c02127df85cebbc015f533992 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_14cf1cfeb9e3d87686cd14f57fb87553 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e657cac9d9d57b3bc03c87f92dcc3600 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec2d512682e628b814341826c3adaba |
| publicationDate | 2014-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-089408-A1 |
| titleOfInvention | NUCLEOSIDS REPLACED, NUCLEOTIDES AND ANALOGS OF THE SAME TO BE EMPLOYED IN THE TREATMENT OF VIRAL DISEASES |
| abstract | Here, nucleosides, nucleotides and analogs thereof, pharmaceutical compositions including one or more nucleosides, nucleotides and analogs thereof and methods for synthesizing them are disclosed. Here, its use is also disclosed in the treatment of a disease and / or a condition - which include an infection caused by a paramyxovirus and / or an orthomyxovirus. Claim 1: A compound selected from formula (1), formula (2) and formula (3), or a pharmaceutically acceptable salt from the foregoing, in which: B¹A, B¹B and B¹C are, independently, a base optionally substituted heterocyclic or a heterocyclic base optionally substituted with a protected amino group; R¹A is selected from the group consisting of hydrogen, an optionally substituted acyl, an optionally substituted O-linked amino acid, or a moiety of the group of formulas (4); when the dotted line (- - - - -) of the formula (1) is a single bond, R²A is CH₂ and R³A is absent; when the dotted line (- - - - -) of the formula (1) is absent, R²A is selected from the group consisting of an optionally substituted C₁₋₆ alkyl, an optionally substituted C₂₋₆ alkenyl, an optionally C₂₋₆ alkynyl substituted, an optionally substituted C₃₋₆ cycloalkyl, an optionally substituted -O-C₁₋₆ alkyl, an optionally substituted C--O-alkenyl, an optionally substituted C₃₋₆ -O-alkynyl and cyano and R³A is selected from the group consisting of OH, -OC (= O) RA and an optionally substituted O-linked amino acid; R¹B is selected from the group consisting of O⁻, OH, a remainder of the group of formulas (5), an optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R¹C and R²C are independently selected from the group consisting of O⁻, OH, an optionally substituted C₁₋₆ alkoxy, a remainder of the group of formulas (6), an optionally substituted N-linked amino acid and an amino acid ester derivative with optionally substituted N bond; or R¹C is a compound of formula (7) and R²C is O⁻ or OH; R²B and R³C are independently selected from the group consisting of an optionally substituted C₁₋₆ alkyl, an optionally substituted C₂₋₆ alkenyl, an optionally substituted C₂₋₆ alkynyl, an optionally substituted C₃₋₆ cycloalkyl, an -O-alkyl Optionally substituted C₁₋₆, an optionally substituted CO -O-alkenyl, an optionally substituted C₃₋₆ -O-alkynyl and cyano; R⁴C is selected from the group consisting of OH, -OC (= O) RC and an optionally substituted O-linked amino acid; R⁴A, R³B and R⁵C are, independently, a halogen; R⁵A, R⁴B and R⁶C are, independently, hydrogen or halogen; R⁶A, R⁷A and R⁸A are independently selected from the group consisting of being absent or being hydrogen, or an optionally substituted C₁₋₂₄ alkyl, an optionally substituted C al alkenyl, an optionally substituted C alqu alkynyl, a C₃₋ cycloalkyl ₆ optionally substituted, an optionally substituted C₃₋₆ cycloalkenyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted aryl (C₁₋₆ alkyl), an optionally substituted * - (CR¹⁵AR¹⁶A) ₚ-O-C, alkyl, an optionally substituted * - (CR¹⁷AR¹⁸A) qO-alkenyl, or a moiety selected from the group of formulas (8); or R⁶A is the compound of formula (9) and R⁷A is absent or is hydrogen; or R⁶A and R⁷A are taken together to form a part selected from the group consisting of an optionally substituted formula residue (10) and optionally substituted formula (11) residue, where the oxygens connected to R⁶A and R⁷A, the phosphorus and the part forms a system of rings of six to ten members; R⁹A is independently selected from the group consisting of an optionally substituted C₁₋₂₄ alkyl, an optionally substituted C₂₋₂₄ alkenyl, an optionally substituted C₂₋₂₄ alkynyl, an optionally substituted C₃₋₆ cycloalkyl, an optionally substituted C₃₋₆ cycloalkenyl , NR³⁰AR³¹A, optionally substituted N-linked amino acid and an optionally substituted N-linked amino acid ester derivative; R¹⁰A and R¹¹A are, independently, an optionally substituted N-linked amino acid or an optionally substituted N-linked amino acid ester derivative; R¹²A, R¹³A and R¹⁴A independently, are absent or are hydrogen; each R¹⁵A, each R¹⁶A, each R¹⁷A and each R¹⁸A are, independently, hydrogen, an optionally substituted C₁₋₂₄ alkyl or alkoxy; R¹⁹A, R²⁰A, R²²A, R²³A, R⁵B, R⁶B, R⁸B and R⁹B, R⁹C, R¹⁰C, R¹²C and R¹³C are independently selected from the group consisting of hydrogen, an optionally substituted C₁₋₂₄ alkyl and an optionally substituted aryl; R²¹A, R²⁴A, R⁷B, R¹⁰B, R¹¹C and R¹⁴C are independently selected from the group consisting of hydrogen, an optionally substituted C₁₋₂₄ alkyl, an optionally substituted aryl, an optionally substituted -O-C-alkyl and an -O -aryl optionally substituted; R¹⁶C, R¹⁷C and R¹⁸C, independently, are absent or hydrogen; R²⁶A and R²⁷A are, independently, -CºN or an optionally substituted substituent, selected from the group consisting of C₂₋₈ organylcarbonyl, C₂₋₈ alkoxycarbonyl and C₂₋₈ organylaminocarbonyl; R²⁸A is selected from the group consisting of hydrogen, an optionally substituted C₁₋₂₄ alkyl, an optionally substituted C₂₋₂₄ alkenyl, an optionally substituted C₂₋₂₄ alkynyl, an optionally substituted C₃₋₆ cycloalkyl and an optionally substituted C₃₋₆ cycloalkenyl; R³⁰A and R³¹A are independently selected from the group consisting of hydrogen, an optionally substituted C₁₋₂₄ alkyl, an optionally substituted C₂₋₂₄ alkenyl, an optionally substituted C₂₋₂₄ alkynyl, an optionally substituted C₃₋₆ cycloalkyl and a C₃ cycloalkenyl ₋₆ optionally substituted; for formula (3), - - - - - is a single bond or a double bond; when - - - - - is a single bond, each R⁷C and each R⁸C is, independently, hydrogen or halogen; and when - - - - - is a double bond, each R⁷C is absent and each R⁸C is independently hydrogen or halogen; RA and RC are, independently, an optionally substituted C₁₋₂₄ alkyl; m and n are, independently, 0 or 1; p and q are independently selected from the group consisting of 1, 2 and 3; r is 1 or 2; Z¹A, Z²A, Z³A, Z⁴A, Z¹B, Z²B and Z¹C are, independently, O or S; and with the proviso that when the dotted line (- - - - -) of the formula (1) is absent; R¹A is a moiety of formula (12) in which R⁸A is an optionally unsubstituted phenyl or C₁₋₄ alkyl with a halogen or methyl and R⁹A is methyl ester, ethyl ester, isopropyl ester, n-butyl ester , benzyl ester or phenyl ester of an amino acid selected from the group consisting of glycine, alanine, valine, leucine, phenylalanine, tryptophan, methionine and proline; R³A is OH; R⁴A is fluoro; R⁵A is fluoro or hydrogen; and B¹A is an unsubstituted uracil; then R²A cannot be -OCH₃; with the proviso that when the dotted line (- - - - -) of the formula (1) is absent; R¹A be H; R³ be OH; R seaA be fluoro; R seaA be fluoro; and B¹A is an unsubstituted cytosine; then R²A cannot be alenil; with the proviso that when the dotted line (- - - - -) of the formula (1) is absent; R¹A be H; R³A is OH; R seaA be fluoro; R⁵A is hydrogen; and B¹A is an unsubstituted thymine; then R²A cannot be C₁ alkyl substituted with an N-amido; and with the proviso that when the dotted line (- - - - -) of the formula (1) is absent; R¹A be H; R³A is OH; R seaA be fluoro; R seaA be fluoro; and B¹A is an unsubstituted cytosine; then R²A cannot be ethynyl. |
| priorityDate | 2011-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 79.